Published in J Natl Compr Canc Netw on June 01, 2011
Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res (2013) 1.87
Causes of death in long-term survivors of head and neck cancer. Cancer (2014) 1.68
p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol (2012) 1.38
Late dysphagia after radiotherapy-based treatment of head and neck cancer. Cancer (2012) 1.23
Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol (2012) 1.00
Role of (18)F-FDG PET-CT in head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital (2013) 0.99
Pretreatment dietary patterns, weight status, and head and neck squamous cell carcinoma prognosis. Am J Clin Nutr (2012) 0.97
Sharing a diagnosis of HPV-related head and neck cancer: the emotions, the confusion, and what patients want to know. Head Neck (2012) 0.93
Solid tumor second primary neoplasms: who is at risk, what can we do? Semin Oncol (2013) 0.92
Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck. Jpn J Clin Oncol (2013) 0.87
Role of stat3 in skin carcinogenesis: insights gained from relevant mouse models. J Skin Cancer (2013) 0.86
Lymph node ratio for postoperative staging of laryngeal squamous cell carcinoma with lymph node metastasis. PLoS One (2014) 0.85
Impact of lymph node ratio on the survival of patients with hypopharyngeal squamous cell carcinoma: a population-based analysis. PLoS One (2013) 0.85
p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary. Head Neck (2014) 0.83
Multidisciplinary clinical approach to the management of head and neck cancer. Eur Arch Otorhinolaryngol (2012) 0.82
High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma. Cancer Med (2013) 0.82
An exploratory study of the informational and psychosocial needs of patients with human papillomavirus-associated oropharyngeal cancer. Oral Oncol (2013) 0.82
Treatment strategies in early-stage oropharyngeal squamous cell carcinoma: a French national survey. Eur Arch Otorhinolaryngol (2015) 0.77
Cigarette use, comorbidities, and prognosis in a prospective head and neck squamous cell carcinoma population. Head Neck (2016) 0.77
Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab. Head Neck (2015) 0.77
The Value of F-18 FDG PET for Planning Treatment and Detecting Recurrence in Malignant Salivary Gland Tumors: Comparison with Conventional Imaging Studies. Nucl Med Mol Imaging (2013) 0.77
Dysplasia at the margin? Investigating the case for subsequent therapy in 'low-risk' squamous cell carcinoma of the oral tongue. Oral Oncol (2013) 0.77
Advancements in the Management of HPV-Associated Head and Neck Squamous Cell Carcinoma. J Clin Med (2015) 0.76
Diagnostic accuracy of ultrasound, ¹⁸F-FDG-PET/CT, and fused ¹⁸F-FDG-PET-MR images with DWI for the detection of cervical lymph node metastases of HNSCC. Clin Oral Investig (2013) 0.76
HPV-related oropharyngeal carcinoma with Overt Level II and/or III metastases at presentation: The risk of subclinical disease in ipsilateral levels IB, IV and V. Acta Oncol (2013) 0.75
Aberrant expression of the S1P regulating enzymes, SPHK1 and SGPL1, contributes to a migratory phenotype in OSCC mediated through S1PR2. Sci Rep (2016) 0.75
Isolation and Characterization of Cancer Stem Cells from Primary Head and Neck Squamous Cell Carcinoma Tumors. Methods Mol Biol (2016) 0.75
Interval between intra-arterial infusion chemotherapy and surgery for locally advanced oral squamous cell carcinoma: impacts on effectiveness of chemotherapy and on overall survival. ScientificWorldJournal (2014) 0.75
A head and neck cancer intervention for use in survivorship clinics: a protocol for a feasibility study. Pilot Feasibility Stud (2016) 0.75
Influence of allelic Variations of hypoxia-related and DNA repair genes on patient outcome and toxicity in head and neck cancer treated with radiotherapy plus cetuximab. Eur Arch Otorhinolaryngol (2015) 0.75
Quality of life during early radiotherapy in patients with head and neck cancer and pain. J Pain Res (2017) 0.75
Activation of Matrix Hyaluronan-Mediated CD44 Signaling, Epigenetic Regulation and Chemoresistance in Head and Neck Cancer Stem Cells. Int J Mol Sci (2017) 0.75
The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care. Acad Pathol (2017) 0.75
Virtual 3-D ¹⁸F-FDG PET/CT panendoscopy for assessment of the upper airways of head and neck cancer patients: a feasibility study. Eur J Nucl Med Mol Imaging (2012) 0.75
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med (2003) 13.99
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol (2003) 11.94
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med (2004) 9.55
Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol (2008) 7.97
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol (2003) 6.82
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med (1991) 6.39
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis (2009) 5.24
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol (2008) 5.04
Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol (2008) 4.39
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol (2010) 4.34
Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck (2005) 4.27
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol (2011) 3.95
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 3.80
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) (2009) 3.70
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol (2008) 3.55
Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res (2003) 3.42
Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2002) 3.39
Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg (2002) 3.37
p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol (2010) 3.37
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol (2007) 3.29
Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope (2006) 3.20
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol (2012) 3.18
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol (2005) 3.12
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol (2012) 3.08
Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis (2004) 3.04
Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol (2012) 3.04
Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol (2013) 3.00
Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer (2008) 2.98
Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol (2006) 2.91
Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck (2010) 2.76
American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol (2006) 2.68
Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer (2008) 2.67
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg (2003) 2.56
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol (2006) 2.53
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol (2002) 2.51
Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res (2009) 2.51
A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid (2008) 2.41
Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol (2010) 2.41
Non-small cell lung cancer. J Natl Compr Canc Netw (2012) 2.40
Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol (2003) 2.38
Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol (2009) 2.38
Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer (2007) 2.37
Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA (2005) 2.37
ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys (2011) 2.36
Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol (2007) 2.36
Parapharyngeal space schwannomas: preoperative imaging determination of the nerve of origin. Arch Otolaryngol Head Neck Surg (2007) 2.32
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol (2006) 2.32
Vascularized tissue to reduce fistula following salvage total laryngectomy: a systematic review. Laryngoscope (2014) 2.21
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol (2005) 2.18
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2012) 2.14
Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res (2006) 2.13
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol (2010) 2.12
Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res (2010) 2.11
Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med (2014) 2.09
Human papillomavirus-associated adenocarcinoma of the base of the tongue. Hum Pathol (2013) 2.08
Prospective functional voice assessment in patients undergoing thyroid surgery. Ann Surg (2002) 2.08
ACR Appropriateness Criteria® ipsilateral radiation for squamous cell carcinoma of the tonsil. Head Neck (2012) 2.07
Primary mucosal malignant melanoma of the head and neck. Head Neck (2002) 2.07
RTOG sarcoma radiation oncologists reach consensus on gross tumor volume and clinical target volume on computed tomographic images for preoperative radiotherapy of primary soft tissue sarcoma of extremity in Radiation Therapy Oncology Group studies. Int J Radiat Oncol Biol Phys (2011) 2.06
Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 2.05
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res (2002) 2.05
Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid (2014) 2.04
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol (2011) 2.03
TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol (2007) 2.03
TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin (2005) 2.03
Thyroid carcinoma. J Natl Compr Canc Netw (2010) 2.02
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res (2012) 2.02
Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys (2004) 2.00
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol (2006) 1.97